Loading...

Deanna Kroetz, PhD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentBioengineering
Address1550 4th Street, Bldg 19B
San Francisco CA 94158
Phone415-476-1159
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    National Pharmaceutical Council 1984  - 1984National Pharmaceutical Council Internship Mortar Board Honor Society Rho Chi National Pharmacy Ho
    Cum Laude Graduate Ohio State University College of Pharmacy1985  - 1985Ohio State University Presidential Scholar Eli Lilly Company Achievement Award
    National Institute of Health Training1987  - 1990National Institute of Health Training Grant Trainee
    Pharmacology Research Associate Training1991  - 1993Pharmacology Research Associate Training (PRAT) Fellowship
    Ohio State University College of Pharmacy1995  - 1995Josephine S. Failer Alumni Award
    American Association of Pharmaceutical Scientists 1996  - 1996American Association of Pharmaceutical Scientists Young Investigator Award in Pharmacokinetics, Phar
    American Society for Clinical Pharmacology and Therapeutics2002  - 2002Leon I. Goldberg Young Investigator Award
    American Heart Association2002  - 2002Elected Fellow, High Blood Pressure Research Council of the American Heart Association
    American Association of Pharmaceutical Scientists2008  - 2008Elected Fellow, American Association of Pharmaceutical Scientists
    Pharmacology2008  - 2008Named to Faculty of 1000, Pharmacology

    Collapse Overview 
    Collapse Overview
    The Kroetz lab has two major research areas. A major goal is to understand the role of genetic variation in determining drug response and toxicity. Integrated genomic and functional studies are focused on identifying genetic biomarkers of taxane-induced sensory peripheral neuropathy and response to antiretroviral therapies. A second area of research is on the role of cytochrome P450 eicosanoids in acute and chronic renal dysfunction. Animal and cellular studies are used to test whether inhibition of soluble epoxide hydrolase can be targeted for renoprotection.


    Collapse Research 
    Collapse Research Activities and Funding
    Pharmacogenomics of Microtubule Targeting Agents
    NIH/NCI R01CA192156Jul 2, 2015 - Jun 30, 2020
    Role: Principal Investigator
    Mechanisms of Renoprotection by Soluble Epoxide Hydrolase Inhibition
    NIH/NIDDK R01DK084147Aug 1, 2010 - Jul 31, 2015
    Role: Principal Investigator
    CYTOCHROME P450 DEPENDENT ARACHIDONIC ACID METABOLISM
    NIH/NHLBI R01HL053994Aug 1, 1996 - Jul 31, 2006
    Role: Principal Investigator
    PHARMACOLOGICAL EFFECTS OF CYTOCHROME P450 4A METABOLISM
    NIH/NHLBI R29HL053994Aug 1, 1996 - Jul 31, 2000
    Role: Principal Investigator
    Pharmaceutical Sciences and Pharmacogenomics
    NIH/NIGMS T32GM007175Jul 1, 1982 - Jun 30, 2022
    Role: Principal Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000079Dec 1, 1974 - Mar 31, 2009
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Global Health
    Collapse Websites
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Bartelink IH, Jones EF, Shahidi-Latham SK, Rong ELP, Zheng Y, Vicini P, van 't Veer L, Wolf D, Iagaru A, Kroetz DL, Prideaux B, Cilliers C, Thurber G, Wimana Z, Gebhart G. Tumor drug penetration measurements could be the neglected piece of the personalized cancer treatment puzzle. Clin Pharmacol Ther. 2018 Aug 14. PMID: 30107040.
      View in: PubMed
    2. Chang JL, Lee S, Tsai AC, Musinguzi N, Muzoora C, Bwana BM, Boum Y, Haberer J, Hunt PW, Martin J, Bangsberg DR, Kroetz DL, Siedner MJ. CYP2B6 genetic polymorphisms, depression, and viral suppression in adults living with HIV initiating efavirenz-containing antiretroviral therapy regimens in Uganda: pooled analysis of two prospective studies. AIDS Res Hum Retroviruses. 2018 Jul 04. PMID: 29973058.
      View in: PubMed
    3. Li M, Mulkey F, Jiang C, O'Neill BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook A, Owzar K, Kroetz D. Identification of a Genomic Region Between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res. 2018 Jun 05. PMID: 29871907.
      View in: PubMed
    4. Eclov RJ, Kim MJ, Smith R, Ahituv N, Kroetz DL. Rare Variants in the ABCG2 Promoter Modulate In Vivo Activity. Drug Metab Dispos. 2018 May; 46(5):636-642. PMID: 29467213.
      View in: PubMed
    5. Sucheston-Campbell LE, Clay-Gilmour AI, Barlow WE, Budd GT, Stram DO, Haiman CA, Sheng X, Yan L, Zirpoli G, Yao S, Jiang C, Owzar K, Hershman D, Albain KS, Hayes DF, Moore HC, Hobday TJ, Stewart JA, Rizvi A, Isaacs C, Salim M, Gralow JR, Hortobagyi GN, Livingston RB, Kroetz DL, Ambrosone CB. Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci. Pharmacogenet Genomics. 2018 02; 28(2):49-55. PMID: 29278617.
      View in: PubMed
    6. Stage TB, Graff M, Wong S, Rasmussen LL, Nielsen F, Pottegård A, Brøsen K, Kroetz DL, Khojasteh SC, Damkier P. Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro. Br J Clin Pharmacol. 2018 Mar; 84(3):510-519. PMID: 29105855.
      View in: PubMed
    7. Stage TB, Bergmann TK, Kroetz DL. Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review. Clin Pharmacokinet. 2018 Jan; 57(1):7-19. PMID: 28612269.
      View in: PubMed
    8. Eclov RJ, Kim MJ, Chhibber A, Smith RP, Ahituv N, Kroetz DL. ABCG2 regulatory single-nucleotide polymorphisms alter in vivo enhancer activity and expression. Pharmacogenet Genomics. 2017 Dec; 27(12):454-463. PMID: 28930109.
      View in: PubMed
    9. Li M, Kroetz DL. Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther. 2018 Feb; 182:152-160. PMID: 28882537.
      View in: PubMed
    10. Eclov RJ, Kim MJ, Smith RP, Liang X, Ahituv N, Kroetz DL. In Vivo Hepatic Enhancer Elements in the Human ABCG2 Locus. Drug Metab Dispos. 2017 02; 45(2):208-215. PMID: 27856528.
      View in: PubMed
    11. Kroetz DL. Best Practices for Clinical and Translational Research and Implementation. Clin Transl Sci. 2016 Aug 22. PMID: 27546282.
      View in: PubMed
    12. Lee SA, Mefford JA, Huang Y, Witte JS, Martin JN, Haas DW, Mclaren PJ, Mushiroda T, Kubo M, Byakwaga H, Hunt PW, Kroetz DL. Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans. AIDS. 2016 Jul 17; 30(11):1807-15. PMID: 27088321; PMCID: PMC4925250 [Available on 07/17/17].
    13. Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens SD, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 01; 22(19):4890-4900. PMID: 27143689.
      View in: PubMed
    14. Yuan B, Yoshino Y, Fukushima H, Markova S, Takagi N, Toyoda H, Kroetz DL. Multidrug resistance-associated protein 4 is a determinant of arsenite resistance. Oncol Rep. 2016 Jan; 35(1):147-54. PMID: 26497925.
      View in: PubMed
    15. Komatsu M, Wheeler HE, Chung S, Low SK, Wing C, Delaney SM, Gorsic LK, Takahashi A, Kubo M, Kroetz DL, Zhang W, Nakamura Y, Dolan ME. Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy. Clin Cancer Res. 2015 Oct 01; 21(19):4337-46. PMID: 26015512; PMCID: PMC4592389 [Available on 10/01/16].
    16. Barbarino JM, Kroetz DL, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for human leukocyte antigen B. Pharmacogenet Genomics. 2015 Apr; 25(4):205-21. PMID: 25647431; PMCID: PMC4356642.
    17. Haenisch S, Zhao Y, Chhibber A, Kaiboriboon K, Do LV, Vogelgesang S, Barbaro NM, Alldredge BK, Lowenstein DH, Cascorbi I, Kroetz DL. SOX11 identified by target gene evaluation of miRNAs differentially expressed in focal and non-focal brain tissue of therapy-resistant epilepsy patients. Neurobiol Dis. 2015 May; 77:127-40. PMID: 25766675; PMCID: PMC4404495.
    18. Chhibber A, Kroetz DL, Tantisira KG, McGeachie M, Cheng C, Plenge R, Stahl E, Sadee W, Ritchie MD, Pendergrass SA. Genomic architecture of pharmacological efficacy and adverse events. Pharmacogenomics. 2014 Dec; 15(16):2025-48. PMID: 25521360; PMCID: PMC4308414.
    19. Barbarino JM, Kroetz DL, Altman RB, Klein TE. PharmGKB summary: abacavir pathway. Pharmacogenet Genomics. 2014 May; 24(5):276-82. PMID: 24625462; PMCID: PMC4074515.
    20. Nicol MR, Fedoriw Y, Mathews M, Prince HM, Patterson KB, Geller E, Mollan K, Mathews S, Kroetz DL, Kashuba AD. Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention. J Clin Pharmacol. 2014 May; 54(5):574-83. PMID: 24343710; PMCID: PMC4061289.
    21. Micheli JE, Chinn LW, Shugarts SB, Patel A, Martin JN, Bangsberg DR, Kroetz DL. Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes? Pharmacogenet Genomics. 2013 Nov; 23(11):591-6. PMID: 23982262; PMCID: PMC4048019.
    22. Markova SM, Kroetz DL. ABCC4 is regulated by microRNA-124a and microRNA-506. Biochem Pharmacol. 2014 Feb 01; 87(3):515-22. PMID: 24184504; PMCID: PMC3927324.
    23. Liu Y, Lu X, Nguyen S, Olson JL, Webb HK, Kroetz DL. Epoxyeicosatrienoic acids prevent cisplatin-induced renal apoptosis through a p38 mitogen-activated protein kinase-regulated mitochondrial pathway. Mol Pharmacol. 2013 Dec; 84(6):925-34. PMID: 24092818; PMCID: PMC3834146.
    24. Motsinger-Reif AA, Jorgenson E, Relling MV, Kroetz DL, Weinshilboum R, Cox NJ, Roden DM. Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics. 2013 Aug; 23(8):383-94. PMID: 20639796; PMCID: PMC3003940.
    25. Tamraz B, Fukushima H, Wolfe AR, Kaspera R, Totah RA, Floyd JS, Ma B, Chu C, Marciante KD, Heckbert SR, Psaty BM, Kroetz DL, Kwok PY. OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis. Pharmacogenet Genomics. 2013 Jul; 23(7):355-64. PMID: 23652407; PMCID: PMC3894639.
    26. Martin MA, Kroetz DL. Abacavir pharmacogenetics--from initial reports to standard of care. Pharmacotherapy. 2013 Jul; 33(7):765-75. PMID: 23649914; PMCID: PMC3700656.
    27. Lewis LD, Miller AA, Owzar K, Bies RR, Markova S, Jiang C, Kroetz DL, Egorin MJ, McLeod HL, Ratain MJ. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics. 2013 Jan; 23(1):29-33. PMID: 23188068; PMCID: PMC3647228.
    28. Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res. 2013 Jan 15; 19(2):491-9. PMID: 23204130; PMCID: PMC3549006.
    29. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst. 2012 Aug 22; 104(16):1264; author reply 1266-8. PMID: 22851270.
      View in: PubMed
    30. Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res. 2012 Sep 15; 18(18):5099-109. PMID: 22843789; PMCID: PMC3445665.
    31. Lee TM, Huang L, Johnson MK, Lizak P, Kroetz D, Aweeka F, Parikh S. In vitro metabolism of piperaquine is primarily mediated by CYP3A4. Xenobiotica. 2012 Nov; 42(11):1088-95. PMID: 22671777.
      View in: PubMed
    32. Nguyen TD, Markova S, Liu W, Gow JM, Baldwin RM, Habashian M, Relling MV, Ratain MJ, Kroetz DL. Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression. Pharmacogenomics J. 2013 Oct; 13(5):396-402. PMID: 22664480; PMCID: PMC3435480.
    33. Liu Y, Webb HK, Fukushima H, Micheli J, Markova S, Olson JL, Kroetz DL. Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor ?B signaling. J Pharmacol Exp Ther. 2012 Jun; 341(3):725-34. PMID: 22414856; PMCID: PMC3362876.
    34. Peppercorn J, Shapira I, Deshields T, Kroetz D, Friedman P, Spears P, Collyar DE, Shulman LN, Dressler L, Bertagnolli MM. Ethical aspects of participation in the database of genotypes and phenotypes of the National Center for Biotechnology Information: the Cancer and Leukemia Group B Experience. Cancer. 2012 Oct 15; 118(20):5060-8. PMID: 22415847.
      View in: PubMed
    35. Yoshino Y, Yuan B, Kaise T, Takeichi M, Tanaka S, Hirano T, Kroetz DL, Toyoda H. Contribution of aquaporin 9 and multidrug resistance-associated protein 2 to differential sensitivity to arsenite between primary cultured chorion and amnion cells prepared from human fetal membranes. Toxicol Appl Pharmacol. 2011 Dec 01; 257(2):198-208. PMID: 21945491; PMCID: PMC3470788.
    36. Marciante KD, Durda JP, Heckbert SR, Lumley T, Rice K, McKnight B, Totah RA, Tamraz B, Kroetz DL, Fukushima H, Kaspera R, Bis JC, Glazer NL, Li G, Austin TR, Taylor KD, Rotter JI, Jaquish CE, Kwok PY, Tracy RP, Psaty BM. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May; 21(5):280-8. PMID: 21386754.
      View in: PubMed
    37. Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, Altman RB. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2011 Mar; 21(3):152-61. PMID: 20216335; PMCID: PMC3098758.
    38. Hoppe R, Brauch H, Kroetz DL, Esteller M. Exploiting the complexity of the genome and transcriptome using pharmacogenomics towards personalized medicine. Genome Biol. 2011; 12(1):301. PMID: 21241526; PMCID: PMC3091296.
    39. Kelly L, Fukushima H, Karchin R, Gow JM, Chinn LW, Pieper U, Segal MR, Kroetz DL, Sali A. Functional hot spots in human ATP-binding cassette transporter nucleotide binding domains. Protein Sci. 2010 Nov; 19(11):2110-21. PMID: 20799350; PMCID: PMC3005782.
    40. Ho RH, Leake BF, Kilkenny DM, Meyer Zu Schwabedissen HE, Glaeser H, Kroetz DL, Kim RB. Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability. Pharmacogenet Genomics. 2010 Jan; 20(1):45-57. PMID: 20010382; PMCID: PMC2883163.
    41. Kroetz DL, Ahituv N, Burchard EG, Guo S, Sali A, Giacomini KM. Institutional Profile: The University of California Pharmacogenomics Center: at the interface of genomics, biological mechanisms and drug therapy. Pharmacogenomics. 2009 Oct; 10(10):1569-76. PMID: 19842929; PMCID: PMC2923222.
    42. Kelly L, Pieper U, Eswar N, Hays FA, Li M, Roe-Zurz Z, Kroetz DL, Giacomini KM, Stroud RM, Sali A. A survey of integral alpha-helical membrane proteins. J Struct Funct Genomics. 2009 Dec; 10(4):269-80. PMID: 19760129.
      View in: PubMed
    43. Hesselson SE, Matsson P, Shima JE, Fukushima H, Yee SW, Kobayashi Y, Gow JM, Ha C, Ma B, Poon A, Johns SJ, Stryke D, Castro RA, Tahara H, Choi JH, Chen L, Picard N, Sjödin E, Roelofs MJ, Ferrin TE, Myers R, Kroetz DL, Kwok PY, Giacomini KM. Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. PLoS One. 2009 Sep 09; 4(9):e6942. PMID: 19742321; PMCID: PMC2735003.
    44. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009 Jun 01; 27(16):2604-14. PMID: 19349540; PMCID: PMC2690389.
    45. Mayer F, Mayer N, Chinn L, Pinsonneault RL, Kroetz D, Bainton RJ. Evolutionary conservation of vertebrate blood-brain barrier chemoprotective mechanisms in Drosophila. J Neurosci. 2009 Mar 18; 29(11):3538-50. PMID: 19295159; PMCID: PMC3040577.
    46. Byakika-Tusiime J, Chinn LW, Oyugi JH, Obua C, Bangsberg DR, Kroetz DL. Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults. PLoS One. 2008; 3(12):e3981. PMID: 19096711; PMCID: PMC2602850.
    47. Fife KL, Liu Y, Schmelzer KR, Tsai HJ, Kim IH, Morisseau C, Hammock BD, Kroetz DL. Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation. J Pharmacol Exp Ther. 2008 Dec; 327(3):707-15. PMID: 18815352; PMCID: PMC2761654.
    48. Tutka P, Dempsey DA, Jacob P, Benowitz NL, Kroetz DL. Nicotine metabolism in pregnant and nonpregnant rabbits. Nicotine Tob Res. 2008 Aug; 10(8):1385-90. PMID: 18686186; PMCID: PMC2923225.
    49. Abla N, Chinn LW, Nakamura T, Liu L, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, Ferrin TE, Giacomini KM, Kroetz DL. The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. J Pharmacol Exp Ther. 2008 Jun; 325(3):859-68. PMID: 18364470; PMCID: PMC2612728.
    50. Gow JM, Hodges LM, Chinn LW, Kroetz DL. Substrate-dependent effects of human ABCB1 coding polymorphisms. J Pharmacol Exp Ther. 2008 May; 325(2):435-42. PMID: 18287207; PMCID: PMC2612726.
    51. Gow JM, Chinn LW, Kroetz DL. The effects of ABCB1 3'-untranslated region variants on mRNA stability. Drug Metab Dispos. 2008 Jan; 36(1):10-5. PMID: 17940136.
      View in: PubMed
    52. Chinn LW, Gow JM, Tse MM, Becker SL, Kroetz DL. Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein. J Antimicrob Chemother. 2007 Jul; 60(1):61-7. PMID: 17510066.
      View in: PubMed
    53. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007 May; 4(2):65-72. PMID: 17547827.
      View in: PubMed
    54. Ng VY, Huang Y, Reddy LM, Falck JR, Lin ET, Kroetz DL. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha. Drug Metab Dispos. 2007 Jul; 35(7):1126-34. PMID: 17431031.
      View in: PubMed
    55. Soranzo N, Kelly L, Martinian L, Burley MW, Thom M, Sali A, Kroetz DL, Goldstein DB, Sisodiya SM. Lack of support for a role for RLIP76 (RALBP1) in response to treatment or predisposition to epilepsy. Epilepsia. 2007 Apr; 48(4):674-83. PMID: 17437410.
      View in: PubMed
    56. Jeong H, Herskowitz I, Kroetz DL, Rine J. Function-altering SNPs in the human multidrug transporter gene ABCB1 identified using a Saccharomyces-based assay. PLoS Genet. 2007 Mar 09; 3(3):e39. PMID: 17352537; PMCID: PMC1817653.
    57. Ng VY, Morisseau C, Falck JR, Hammock BD, Kroetz DL. Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1. Arterioscler Thromb Vasc Biol. 2006 Nov; 26(11):2462-8. PMID: 16917105; PMCID: PMC1904341.
    58. Kroetz DL. Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity. J Clin Oncol. 2006 Sep 10; 24(26):4225-7. PMID: 16895999.
      View in: PubMed
    59. Xu F, Ng VY, Kroetz DL, de Montellano PR. CYP4 isoform specificity in the omega-hydroxylation of phytanic acid, a potential route to elimination of the causative agent of Refsum's disease. J Pharmacol Exp Ther. 2006 Aug; 318(2):835-9. PMID: 16707724.
      View in: PubMed
    60. Komoto C, Nakamura T, Sakaeda T, Kroetz DL, Yamada T, Omatsu H, Koyama T, Okamura N, Miki I, Tamura T, Aoyama N, Kasuga M, Okumura K. MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet. 2006 Apr; 21(2):126-32. PMID: 16702732.
      View in: PubMed
    61. Shu Y, Urban TJ, Leabman MK, Fujita T, Erdman AR, Lagpacan LL, Brown C, Castro RA, Huang CC, Stryke D, Kawamoto M, Johns SJ, Taylor TR, Chan W, De La Cruz M, Carlson EJ, Ferrin TE, Brett CM, Burchard EG, Herskowitz I, Kroetz DL, Giacomini KM. PharmGKB submission update: V. PMT submissions of genetic variation in SLC22 family transporters. Pharmacol Rev. 2006 Mar; 58(1):3-4. PMID: 16507878.
      View in: PubMed
    62. Nguyen TD, Gow JM, Chinn LW, Kelly L, Jeong H, Huang CC, Stryke D, Kawamoto M, Johns SJ, Carlson E, Taylor T, Ferrin TE, Sali A, Giacomini KM, Kroetz DL. PharmGKB submission update: IV. PMT submissions of genetic variations in ATP-Binding cassette transporters to the PharmGKB network. Pharmacol Rev. 2006 Mar; 58(1):1-2. PMID: 16507877.
      View in: PubMed
    63. Badagnani I, Sorani M, Edwards RH, Brown C, Castro RA, Huang CC, Stryke D, Kawamoto M, Johns SJ, Carlson EJ, Taylor T, Chan W, De La Cruz M, Ferrin TE, Burchard EG, Herskowitz I, Kroetz DL, Giacomini KM. PharmGKB submission update: VI. PMT submissions of genetic variations in neurotransmitter transporters (SLC6, SLC17, and SLC18) to the PharmGKB network. Pharmacol Rev. 2006 Mar; 58(1):5-6. PMID: 16507879.
      View in: PubMed
    64. Yu Z, Ng VY, Su P, Engler MM, Engler MB, Huang Y, Lin E, Kroetz DL. Induction of renal cytochrome P450 arachidonic acid epoxygenase activity by dietary gamma-linolenic acid. J Pharmacol Exp Ther. 2006 May; 317(2):732-8. PMID: 16421287.
      View in: PubMed
    65. Andersson T, Flockhart DA, Goldstein DB, Huang SM, Kroetz DL, Milos PM, Ratain MJ, Thummel K. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther. 2005 Dec; 78(6):559-81. PMID: 16338273.
      View in: PubMed
    66. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadée W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics. 2005 Oct; 15(10):693-704. PMID: 16141795.
      View in: PubMed
    67. Kroetz DL, Xu F. Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation. Annu Rev Pharmacol Toxicol. 2005; 45:413-38. PMID: 15822183.
      View in: PubMed
    68. Pauli-Magnus C, Kroetz DL. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res. 2004 Jun; 21(6):904-13. PMID: 15212152.
      View in: PubMed
    69. Yu Z, Davis BB, Morisseau C, Hammock BD, Olson JL, Kroetz DL, Weiss RH. Vascular localization of soluble epoxide hydrolase in the human kidney. Am J Physiol Renal Physiol. 2004 Apr; 286(4):F720-6. PMID: 14665429.
      View in: PubMed
    70. Xu F, Falck JR, Ortiz de Montellano PR, Kroetz DL. Catalytic activity and isoform-specific inhibition of rat cytochrome p450 4F enzymes. J Pharmacol Exp Ther. 2004 Mar; 308(3):887-95. PMID: 14634044.
      View in: PubMed
    71. Pauli-Magnus C, Feiner J, Brett C, Lin E, Kroetz DL. No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin Pharmacol Ther. 2003 Nov; 74(5):487-98. PMID: 14586389.
      View in: PubMed
    72. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Carlson EJ, Herskowitz I, Giacomini KM, Clark AG. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 2003 Aug; 13(8):481-94. PMID: 12893986.
      View in: PubMed
    73. Leabman MK, Huang CC, DeYoung J, Carlson EJ, Taylor TR, de la Cruz M, Johns SJ, Stryke D, Kawamoto M, Urban TJ, Kroetz DL, Ferrin TE, Clark AG, Risch N, Herskowitz I, Giacomini KM. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A. 2003 May 13; 100(10):5896-901. PMID: 12719533; PMCID: PMC156298.
    74. Xu F, Straub WO, Pak W, Su P, Maier KG, Yu M, Roman RJ, Ortiz De Montellano PR, Kroetz DL. Antihypertensive effect of mechanism-based inhibition of renal arachidonic acid omega-hydroxylase activity. Am J Physiol Regul Integr Comp Physiol. 2002 Sep; 283(3):R710-20. PMID: 12185006.
      View in: PubMed
    75. Pauli-Magnus C, Kroetz DL. MDR1 reference sequence and reference function. Clin Pharmacol Ther. 2002 Jul; 72(1):100-1. PMID: 12152008.
      View in: PubMed
    76. Kroetz DL, Zeldin DC. Cytochrome P450 pathways of arachidonic acid metabolism. Curr Opin Lipidol. 2002 Jun; 13(3):273-83. PMID: 12045397.
      View in: PubMed
    77. LeBrun LA, Xu F, Kroetz DL, Ortiz de Montellano PR. Covalent attachment of the heme prosthetic group in the CYP4F cytochrome P450 family. Biochemistry. 2002 May 07; 41(18):5931-7. PMID: 11980497.
      View in: PubMed
    78. Ring HZ, Kroetz DL. Candidate gene approach for pharmacogenetic studies. Pharmacogenomics. 2002 Jan; 3(1):47-56. PMID: 11966402.
      View in: PubMed